FindTrial
Sign In

Intravenous Labetalol for intracerebral hemorrhage

Assessment of Safety and efficacy of continuous intravenous Labetalol infusion for blood pressure control in patients with spontaneous intracerebral hemorrhage

Status
Unknown
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20240423003
Enrollment
100
Registered
2024-04-23
Start date
2023-11-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood pressure control and hematoma volume control in patients with spontaneous intracerebral hemorrhage intracranial hemorrhage Labetalol blood pressure hemorrhagic stroke

Interventions

Patients with spontaneous ICH who received continuous intravenous Labetalol infusion for blood pressure control
Treatment
Spontaneous ICH patients who received continuous intravenous Labetalol infusion

Sponsors

Faculty of Medicine, Thammasat University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Spontaneous ICH 2.Age more than 18 years 3. No secondary causes: AVM, aneurysm

Exclusion criteria

Exclusion criteria: 1.Secondary causes of ICH: AVM, aneurysm 2.Pregnancy 3.Traumatic intracerebral hemorrhage

Design outcomes

Primary

MeasureTime frame
Safety 24 hours modified Rankin scale—

Secondary

MeasureTime frame
Complications 24 hours Blood pressure less than 90/60 mmHg, Heart rate less than 50 beat per minute,Dosage related to complications 24 hours milligrams per day,Target blood pressure 24 hours Time required for BP to reach target BP/ Hours,Hematoma expansion 24 hours Hematoma volume of more than 33% from baseline—

Countries

Thailand

Contacts

Public ContactRaywat Noiphithak

Thammasat University

raywat_n@tu.ac.th0877799798

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026